Ashwini Shami of OmniScience Capital has cautioned investors about high valuations in new-age and mid-cap stocks, suggesting prices have run ahead of actual earnings. He advises a shift toward high-quality, reasonably priced growth as macroeconomic pressures mount. Investors may track whether company earnings can justify current price premiums.
Ashwini Shami, President of OmniScience Capital, has issued a note of caution regarding the current state of high-growth sectors, particularly new-age firms and mid-cap stocks. He argues that many of these stocks are trading at prices that have already factored in years of future earnings growth, leaving little room for error if company results miss market expectations.
The core of the concern lies in the valuation gap. For context, the Nifty Midcap 150 index is currently trading at a price-to-earnings (P/E) ratio of approximately 27.43. This metric, which represents how much investors are paying for every rupee of earnings, suggests that the market is paying a high premium for growth that may not materialize quickly. In comparison, larger-cap indices like the Nifty 100 have maintained more modest valuations near 20x.
The firm is specifically flagging sectors such as consumer durables, private sector defense, tourism, real estate, and FMCG as areas where stock prices have reached levels that may not justify the potential returns. In these segments, Shami notes that the cost of capital is now difficult to outpace with earnings, making the risk-reward balance unfavorable for new investors.
Beyond stock-specific valuations, the broader market faces external headwinds. Concerns including the ongoing West Asia conflict, persistent inflation, and currency depreciation are creating a restrictive environment. These factors can reduce the ability of the Reserve Bank of India to lower interest rates to boost demand, which puts pressure on growth-focused companies that rely on easy liquidity.
Rather than chasing high-momentum, expensive stocks, OmniScience Capital emphasizes a framework they term Scientific Investing. This approach focuses on identifying companies with consistent, high-quality growth at reasonable prices. They highlight areas like capital goods and infrastructure as sectors with more potential, given the ongoing public and private spending push. For investors, the current consolidation phase serves as a reminder to check if the growth priced into a stock is realistic, rather than betting on speculative rallies. The main monitorable for investors will be whether companies can deliver the earnings growth required to support these higher valuations in coming quarters.